Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema vs Diet on Energy Metabolism in Obesity
NCT07184086Phase 1Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Sep 2025
- Primary completion
- Oct 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CagriSema in obesity (2 arms), sponsored by Novo Nordisk. Primary endpoint: Sleeping Metabolic Rate at 20 weeks. Started Sep 2025; status: active, not recruiting.
02
Drugs
CagriSema
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07184086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07184086.